RBC Capital Maintains Outperform on Amedisys, Raises Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Ben Hendrix has maintained an Outperform rating on Amedisys (NASDAQ:AMED) and increased the price target from $97 to $100.
March 25, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has maintained an Outperform rating on Amedisys and raised the price target from $97 to $100.
The maintenance of an Outperform rating combined with an increase in the price target by RBC Capital suggests a strong bullish sentiment towards Amedisys. This is likely to instill confidence in investors and could lead to a short-term positive impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100